Open in Screener

NEUE

NeueHealth Inc

Oct 02 • 04:00PM ET

6.75

0.00 0.00 %

Healthcare • Healthcare Plans • USA • NYSE

Peers: UNH CI HUM CNC MOH HCA THC UHS ACHC CRL

Index	-	P/E	-	EPS (ttm)	-15.97	Insider Own	66.66%	Shs Outstand	9.02M	Perf Week	0.64%
Market Cap	60.91M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.55%	Shs Float	3.01M	Perf Month	0.49%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	6.99%	Short Float	0.56%	Perf Quarter	-1.70%
Income	-134.80M	P/S	0.07	EPS this Y	-	Inst Trans	-	Short Ratio	2.70	Perf Half Y	2.32%
Sales	890.44M	P/B	-	EPS next Y	-	ROA	-11.55%	Short Interest	0.02M	Perf YTD	-8.99%
Book/sh	-151.72	P/C	-	EPS next 5Y	-	ROE	-	52W High	7.66 -11.84%	Perf Year	29.37%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	46.84% -7.17%	ROIC	-	52W Low	3.79 78.18%	Perf 3Y	-92.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-14.77% 27.26%	Gross Margin	-	Volatility	1.63% 2.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	87.09%	Oper. Margin	-3.26%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-13.83%	Profit Margin	-15.14%	RSI (14)	53.05	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.70	EPS Q/Q	69.74%	SMA20	0.42%	Beta	0.60	Target Price	7.00
Payout	-	Debt/Eq	-	Sales Q/Q	-7.48%	SMA50	0.74%	Rel Volume	0.00	Prev Close	6.75
Employees	986	LT Debt/Eq	-	Earnings	Aug 07 BMO	SMA200	0.13%	Avg Volume	6.29K	Price	6.75
IPO	Jun 24, 2021	Option/Short	No / No	EPS/Sales Surpr.	-1427.27% -4.44%	Trades		Volume	180	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-11-22	Downgrade	JP Morgan	Neutral → Underweight
Mar-29-22	Downgrade	JP Morgan	Overweight → Neutral
Mar-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$9 → $3
Mar-02-22	Downgrade	BofA Securities	Buy → Underperform
Jan-10-22	Resumed	Citigroup	Neutral	$5 → $3.50
Dec-16-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $4
Dec-14-21	Initiated	Goldman	Neutral	$5
Dec-10-21	Upgrade	JP Morgan	Neutral → Overweight	$6
Nov-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$13 → $5
Nov-02-21	Downgrade	Cowen	Outperform → Market Perform	$14 → $9
Nov-01-21	Downgrade	Citigroup	Buy → Neutral
Sep-10-21	Initiated	Cowen	Outperform	$14
Aug-04-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$12
Aug-04-21	Upgrade	Citigroup	Neutral → Buy	$16 → $12
Jul-19-21	Initiated	Wolfe Research	Peer Perform	$15
Jul-19-21	Initiated	RBC Capital Mkts	Outperform	$22
Jul-19-21	Initiated	Piper Sandler	Overweight	$24
Jul-19-21	Initiated	Morgan Stanley	Equal-Weight	$18
Jul-19-21	Initiated	JP Morgan	Neutral	$19
Jul-19-21	Initiated	Goldman	Buy	$36

Show Previous Ratings

Oct-02-25 09:16AM	NeueHealth Announces Closing of Take-Private Transaction (Business Wire)
Aug-07-25 06:56AM	NeueHealth: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	NeueHealth Reports Second Quarter 2025 Results (Business Wire)
Jul-17-25 08:00AM	NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025 (Business Wire)
Jul-16-25 06:45AM	Premier Medical Collaborates with Walgreens to Expand Access to Care Across Central Florida (Business Wire)
11:28AM	Loading…
Jun-02-25 11:28AM	Elevation Point Adds Former Orion CEO Eric Clarke to Board of Directors (Wealth Management)
May-09-25 03:13AM	NeueHealth Inc (NEUE) Q1 2025 Earnings Call Highlights: Strong Consumer Growth and Continued ... (GuruFocus.com)
May-08-25 06:45AM	NeueHealth Reports First Quarter 2025 Results (Business Wire)
Apr-23-25 08:00AM	NeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025 (Business Wire)
Mar-20-25 01:14PM	NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript (SeekingAlpha) +8.88%
06:45AM	NeueHealth Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-26-25 08:00AM	NeueHealth to Host Fourth Quarter 2024 Earnings Conference Call on March 20, 2025 (Business Wire)
Dec-23-24 05:53PM	NeueHealth to Be Taken Private by NEA and Consortium of Investors (Business Wire) +12.83% +74.94%
Nov-07-24 06:45AM	Neuehealth Reports Third Quarter 2024 Results (Business Wire) +6.36%
Oct-30-24 06:45AM	NeueHealth Acquires Full Ownership of Centrum Health (Business Wire)
08:00AM	Loading…
Oct-17-24 08:00AM	NeueHealth to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024 (Business Wire) -5.68%
Sep-19-24 12:00PM	NeueHealth (NEUE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +6.94%
Aug-07-24 06:45AM	NeueHealth Reports Second Quarter 2024 Results (Business Wire)
Jul-18-24 08:00AM	NeueHealth to Host Second Quarter 2024 Earnings Conference Call on August 7, 2024 (Business Wire)
Jun-24-24 06:45AM	NeueHealth Secures up to $150 Million in New Term Loan Facility with Hercules Capital (Business Wire)
Jun-18-24 04:30PM	NeueHealth Receives NYSE Non-Compliance Letter Regarding Market Capitalization Requirements (Business Wire)
Jun-06-24 07:47AM	NEUE Stock Earnings: NeueHealth Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-11-24 08:41AM	NeueHealth, Inc. (NYSE:NEUE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 06:45AM	NeueHealth Reports First Quarter 2024 Results (Business Wire)
Apr-18-24 08:00AM	NeueHealth to Host First Quarter 2024 Earnings Conference Call on May 8, 2024 (Business Wire) +8.05%
Apr-09-24 05:29PM	NeueHealth Enters into Amendment to its Credit Facility (Business Wire) +6.57%
Mar-06-24 08:01AM	NEUE Stock Earnings: NeueHealth Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +18.13%
06:45AM	NeueHealth Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Feb-20-24 08:00AM	NeueHealth to Host Fourth Quarter 2023 Earnings Conference Call on March 6, 2024 (Business Wire)
Jan-18-24 05:38AM	Bright Health rebrands as NeueHealth, distances itself from insurance portfolio (Healthcare Dive)
04:05PM	Loading…
Jan-17-24 04:05PM	Bright Health Group Adopts NeueHealth as Corporate Brand Name (Business Wire)
Jan-02-24 04:30PM	Bright Health Group Closes the Sale of its California Medicare Advantage Business to Molina Healthcare (Business Wire) +8.13% +10.91%
Dec-29-23 06:45AM	Bright Health Group Strengthens Capital Position with Amendment to its Credit Facility, Impending Close of the Sale of its California Medicare Advantage Business (Business Wire) +45.06%
Nov-09-23 01:23PM	Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 09:33AM	Bright Health: Q3 Earnings Snapshot (Associated Press Finance)
07:26AM	Bright Health Group Inc (BHG) Reports Q3 2023 Earnings: Revenue Up 39% YoY, Net Loss of $479. ... (GuruFocus.com)
06:45AM	Bright Health Group Reports Third Quarter 2023 Results (Business Wire)
Oct-13-23 08:00AM	Bright Health Group to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023 (Business Wire)
Sep-19-23 06:45AM	Bright Health Group Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down (Business Wire)
Aug-09-23 08:53PM	Q2 2023 Bright Health Group Inc Earnings Call (Thomson Reuters StreetEvents) -12.34% -10.84%
08:05AM	Bright Health Group (BHG) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:54AM	Bright Health: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Bright Health Group Reports Second Quarter 2023 Results (Business Wire)
Aug-07-23 06:45AM	Bright Health Group Secures Financing to Support Operations Pending the Expected Close of California Medicare Advantage Business Sale (Business Wire)
Aug-02-23 08:15AM	Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates (Zacks)
Jul-17-23 08:00AM	Bright Health Group to Host Second Quarter 2023 Earnings Conference Call on August 9, 2023 (Business Wire)
Jul-13-23 06:20AM	Investors in Bright Health Group (NYSE:BHG) from a year ago are still down 89%, even after 26% gain this past week (Simply Wall St.) -5.61%
Jul-12-23 03:29PM	A 1,462% Bet on Tiny Health-Care Firm Shows Option Math Is Hard (Bloomberg) +6.25%
Jul-03-23 12:24PM	Molina (MOH) to Buy Bright Health's California Medicare Business (Zacks) -7.94%
08:41AM	Strength Seen in Bright Health (BHG): Can Its 11.9% Jump Turn into More Strength? (Zacks)
Jun-30-23 06:45AM	Bright Health Group Enters into Definitive Agreement with Molina Healthcare to Sell its California Medicare Advantage Business, Bolstering Capital Position to Continue Advancing its Value-Driven Care Model (Business Wire) +11.90%
Jun-09-23 07:59AM	11 Best Health Insurance Stocks to Buy (Insider Monkey)
May-09-23 08:05AM	Bright Health Group (BHG) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +52.94%
06:57AM	Bright Health: Q1 Earnings Snapshot (AP Finance)
06:45AM	Bright Health Group Reports First Quarter 2023 Results (Business Wire)
May-03-23 05:00PM	Bright Health Group Appoints Jay Matushak as Chief Financial Officer (Business Wire)
Apr-28-23 08:00AM	Bright Health Group to Explore Strategic Alternatives for Medicare Advantage Business as it Focuses on Driving Performance through its Consumer Care Delivery Business (Business Wire)
Apr-25-23 04:05PM	Bright Health Group to Host First Quarter 2023 Earnings Conference Call on May 9, 2023 (Business Wire)
Mar-29-23 07:20AM	Bright Health Group, Inc.'s (NYSE:BHG) market cap dropped US$31m last week; Private equity firms bore the brunt (Simply Wall St.)
Mar-02-23 09:19PM	Bright Health Group, Inc. (NYSE:BHG) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.16%
05:38AM	Bright Health Group Full Year 2022 Earnings: US$1.23 loss per share (vs US$3.02 loss in FY 2021) (Simply Wall St.)
02:30AM	Q4 2022 Bright Health Group Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-01-23 08:05AM	Bright Health Group (BHG) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -42.05%
06:45AM	Bright Health Group Reports Fourth Quarter and Full Year 2022 Results (Business Wire)
Feb-22-23 08:05PM	Icon PLC (ICLR) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-14-23 07:08AM	Bullish Bright Health Group, Inc. (NYSE:BHG) insiders filled their treasuries with US$1.4m worth of stock over last year (Simply Wall St.)
Feb-10-23 01:50PM	25 Biggest Minnesota Companies and Stocks (Insider Monkey)
08:00AM	Bright Health Group to Host Fourth Quarter 2022 Earnings Conference Call on March 1, 2023 (Business Wire)
Feb-01-23 03:15PM	Bright Health plans 2nd round of layoffs at Bloomington headquarters (American City Business Journals) +7.35%
Jan-18-23 05:51AM	Bright Health Group (NYSE:BHG) shareholders are up 31% this past week, but still in the red over the last year (Simply Wall St.) -16.34%
Jan-10-23 07:00AM	Bright Health Group Announces Updated 2023 Expectations Ahead of J.P. Morgan Healthcare Conference Presentation (Business Wire) +25.23%
Jan-04-23 12:00PM	Bright Health (BHG) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-21-22 08:46AM	Bright Health Group to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-22 04:30PM	Bright Health Group Receives Continued Listing Standard Notice from NYSE (Business Wire) +5.93% -16.12%
Nov-10-22 04:30PM	CORRECTING and REPLACING Bright Health Group Reports Third Quarter 2022 Results (Business Wire) +14.26% -8.54%
Nov-09-22 03:37PM	NeueHealth and Medical Home Network Partner to Reduce Health Care Disparities through New ACO REACH Model (PR Newswire) -8.75%
02:42PM	Bright Health to lay off 99 local employees after individual health insurance exit (American City Business Journals)
08:05AM	Bright Health Group (BHG) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-22 08:05AM	Viatris (VTRS) Q3 Earnings Beat Estimates (Zacks)
Oct-19-22 07:30AM	Bright Health Group to Host Third Quarter 2022 Earnings Conference Call on November 9, 2022 (Business Wire) -6.76%
Oct-18-22 07:30AM	Bright Health Group Announces Closing of $175 Million Capital Raise to Support Focused Business (Business Wire)
Oct-11-22 03:16PM	Bright Health drops individual health insurance business, raises $175M (American City Business Journals) +28.57%
07:00AM	Bright Health Group to Further Focus on Delivering Affordable Healthcare to Aging and Underserved Populations Through Its Fully Aligned Care Model in Florida, Texas, and California (Business Wire)
Sep-13-22 02:22PM	Bright Health Group, Inc.'s (NYSE:BHG) market cap surged US$157m last week, private equity firms who have a lot riding on the company were rewarded (Simply Wall St.) -9.52%
Aug-10-22 04:00PM	Bright Health Group, Inc. (BHG) Q2 2022 Earnings Call Transcript (Motley Fool) -11.86%
07:55AM	Bright Health Group (BHG) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:45AM	Bright Health Group Reports Second Quarter 2022 Results (Business Wire)
Aug-08-22 05:45PM	DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-22 03:06PM	The List: Minnesota CEOs ranked by total compensation (American City Business Journals)
Aug-04-22 06:15PM	Doximity (DOCS) Tops Q1 Earnings and Revenue Estimates (Zacks)
Jul-26-22 08:00AM	Bright Health Group to Host Second Quarter 2022 Earnings Conference Call on August 10, 2022 (Business Wire)
Jul-25-22 05:45PM	Medpace (MEDP) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-22-22 11:25AM	Bright Health Group (NYSE:BHG) shareholders are up 7.0% this past week, but still in the red over the last year (Simply Wall St.) -7.07%
Jun-22-22 11:18AM	Bright Health Group, Inc. (NYSE:BHG) insiders need another US$3.3m to breakeven on a US$4.5m stock purchase even after recent gains (Simply Wall St.)
May-17-22 04:05PM	Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses (Business Wire)
May-08-22 08:21AM	Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report (Simply Wall St.)
May-04-22 04:01PM	Bright Health Group, Inc. (BHG) Q1 2022 Earnings Call Transcript (Motley Fool) +33.33%
06:45AM	Bright Health Group Reports First Quarter 2022 Results (Business Wire)
Apr-19-22 08:30AM	Bright Health Group to Host First Quarter 2022 Earnings Conference Call on May 4, 2022 (Business Wire)
Apr-14-22 05:26PM	True Health parent company to discontinue insurance plans for New Mexicans (American City Business Journals) -5.91%

NeueHealth, Inc. engages in the provision of healthcare products and services for consumers and care providers in local markets. The firm offers individual, family, and Medicare advantage health plans. It operates through the NeueCare and NeueSolutions segments. The NeueCare segment delivers healthcare to all populations across the ACA marketplace, Medicare, and Medicaid through owned and affiliated clinics. The NeueSolutions segment provides a suite of technology, services, and clinical care solutions. The company was founded by Robert J. Sheehy, Tomas Valdivia, and Kyle Rolfing in 2015 and is headquartered in Doral, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Makhzoumi Mohamad	Director	Oct 02 '25	Option Exercise	0.01	3,948,675	39,487	2,385,055	Oct 06 05:54 PM
SANDELL SCOTT D	Director	Oct 02 '25	Option Exercise	0.01	1,116,765	11,168	2,385,055	Oct 06 05:54 PM
SANDELL SCOTT D	Director	Oct 02 '25	Sale	6.75	4,195	28,316	488,702	Oct 06 05:54 PM
Florence Anthony A. Jr.	Director	Oct 02 '25	Option Exercise	0.01	1,116,765	11,168	2,385,055	Oct 06 05:53 PM
Florence Anthony A. Jr.	Director	Oct 02 '25	Sale	6.75	4,195	28,316	488,702	Oct 06 05:53 PM
Walker Paul Edward	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:53 PM
Walker Paul Edward	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:53 PM
Chang Carmen	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:52 PM
Chang Carmen	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:52 PM
Behbahani Ali	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:52 PM
Behbahani Ali	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:52 PM
Yang Rick	Director	Oct 02 '25	Option Exercise	0.01	310,213	3,102	2,385,055	Oct 06 05:51 PM
Yang Rick	Director	Oct 02 '25	Sale	6.75	3,635	24,536	488,702	Oct 06 05:51 PM
Mathers Edward T	Director	Oct 02 '25	Option Exercise	0.01	310,213	3,102	2,385,055	Oct 06 05:50 PM
Mathers Edward T	Director	Oct 02 '25	Sale	6.75	3,635	24,536	488,702	Oct 06 05:50 PM
BASKETT FOREST	Director	Oct 02 '25	Option Exercise	0.01	992,680	9,927	1,961,234	Oct 06 05:50 PM
BASKETT FOREST	Director	Oct 02 '25	Sale	6.75	840	5,670	488,702	Oct 06 05:50 PM
NEA 18 Venture Growth Equity,	Director	Oct 02 '25	Option Exercise	0.01	124,085	1,241	2,385,055	Oct 06 05:49 PM
NEA 18 Venture Growth Equity,	Director	Oct 02 '25	Sale	6.75	3,355	22,646	1,654,334	Oct 06 05:49 PM
New Enterprise Associates 17,	Director	Oct 02 '25	Option Exercise	0.01	186,128	1,861	674,830	Oct 06 05:49 PM
New Enterprise Associates 17,	Director	Oct 02 '25	Sale	6.75	280	1,890	488,702	Oct 06 05:49 PM
New Enterprise Associates 16,	Director	Oct 02 '25	Option Exercise	0.01	372,255	3,723	1,160,234	Oct 06 05:48 PM
New Enterprise Associates 16,	Director	Oct 02 '25	Sale	6.75	280	1,890	787,979	Oct 06 05:48 PM
NEA 15 GP, LLC	Director	Oct 02 '25	Option Exercise	0.01	434,297	4,343	1,961,234	Oct 06 05:48 PM
NEA 15 GP, LLC	Director	Oct 02 '25	Sale	6.75	280	1,890	1,526,937	Oct 06 05:48 PM
New Enterprise Associates 15,	Director	Oct 02 '25	Option Exercise	0.01	434,297	4,343	1,961,234	Oct 06 05:48 PM
New Enterprise Associates 15,	Director	Oct 02 '25	Sale	6.75	280	1,890	1,526,937	Oct 06 05:48 PM
IMMELT JEFFREY R	Director	May 13 '25	Option Exercise	0.00	10,500	0	23,919	May 15 06:45 PM
ADKINS KEDRICK D JR	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:39 PM
Kadre Manuel	Director	May 13 '25	Option Exercise	0.00	10,500	0	29,820	May 15 06:34 PM
Gooden Linda R	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:27 PM
Sheehy Robert J	Director	May 13 '25	Option Exercise	0.00	10,500	0	15,255	May 15 06:20 PM
Makhzoumi Mohamad	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:18 PM
Kraus Stephen	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,444	May 15 06:15 PM
Manders Matthew G	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,741	May 15 06:15 PM
Slavitt Andrew M	Director	May 13 '25	Option Exercise	0.00	10,500	0	18,529	May 15 06:07 PM
Scherman Jeffrey J	Chief Accounting Officer	May 12 '25	Sale	6.76	112	757	12,463	May 14 05:23 PM
Matushak Jay	Chief Financial Officer	May 12 '25	Sale	6.76	472	3,191	40,556	May 14 05:21 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 13 '25	Sale	6.74	1,020	6,875	12,587	Mar 17 08:40 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 14 '25	Sale	6.13	353	2,164	12,234	Mar 17 08:40 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 13 '25	Sale	6.74	2,595	17,490	21,003	Mar 17 08:39 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 14 '25	Sale	6.13	899	5,511	20,104	Mar 17 08:39 PM
Orozco Tomas	EVP, Consumer Care	Mar 13 '25	Sale	6.74	3,540	23,860	30,551	Mar 17 08:38 PM
Orozco Tomas	EVP, Consumer Care	Mar 14 '25	Sale	6.13	1,226	7,515	29,325	Mar 17 08:38 PM
Matushak Jay	Chief Financial Officer	Mar 13 '25	Sale	6.74	4,448	29,980	41,592	Mar 17 08:37 PM
Matushak Jay	Chief Financial Officer	Mar 14 '25	Sale	6.13	1,542	9,452	40,050	Mar 17 08:37 PM
Mikan George Lawrence III	CEO & President	Mar 13 '25	Sale	6.74	35,896	241,939	261,894	Mar 17 08:36 PM
Mikan George Lawrence III	CEO & President	Mar 14 '25	Sale	6.13	12,440	76,257	249,454	Mar 17 08:36 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 11 '25	Sale	6.85	427	2,925	8,482	Mar 13 09:55 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 12 '25	Sale	6.93	375	2,599	13,607	Mar 13 09:55 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 12 '25	Sale	6.93	953	6,604	23,598	Mar 13 09:52 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 11 '25	Sale	6.85	195	1,336	10,551	Mar 13 09:52 PM
Orozco Tomas	EVP, Consumer Care	Mar 12 '25	Sale	6.93	1,300	9,009	34,091	Mar 13 09:49 PM
Orozco Tomas	EVP, Consumer Care	Mar 11 '25	Sale	6.85	617	4,226	11,391	Mar 13 09:49 PM
Matushak Jay	Chief Financial Officer	Mar 12 '25	Sale	6.93	1,633	11,317	46,040	Mar 13 09:47 PM
Matushak Jay	Chief Financial Officer	Mar 11 '25	Sale	6.85	814	5,576	23,673	Mar 13 09:47 PM
Mikan George Lawrence III	CEO & President	Mar 12 '25	Sale	6.93	13,180	91,337	297,790	Mar 13 09:45 PM
Mikan George Lawrence III	CEO & President	Mar 11 '25	Sale	6.85	3,747	25,667	180,970	Mar 13 09:45 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 07 '25	Sale	7.19	620	4,458	7,813	Mar 11 09:51 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 10 '25	Sale	7.06	184	1,299	8,909	Mar 11 09:51 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 07 '25	Sale	7.19	1,240	8,916	10,167	Mar 11 09:51 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 10 '25	Sale	7.06	2	14	10,746	Mar 11 09:51 PM
Orozco Tomas	EVP, Consumer Care	Mar 07 '25	Sale	7.19	620	4,458	9,701	Mar 11 09:50 PM
Orozco Tomas	EVP, Consumer Care	Mar 10 '25	Sale	7.06	20	141	12,008	Mar 11 09:50 PM
Matushak Jay	Chief Financial Officer	Mar 07 '25	Sale	7.19	1,860	13,373	22,227	Mar 11 09:50 PM
Matushak Jay	Chief Financial Officer	Mar 10 '25	Sale	7.06	184	1,299	24,487	Mar 11 09:50 PM
Mikan George Lawrence III	CEO & President	Mar 07 '25	Sale	7.19	26,660	191,685	178,756	Mar 11 09:49 PM
Mikan George Lawrence III	CEO & President	Mar 10 '25	Sale	7.06	1,604	11,324	184,717	Mar 11 09:49 PM
Scherman Jeffrey J	Chief Accounting Officer	Jan 06 '25	Sale	7.33	1,368	10,027	5,942	Jan 08 08:58 PM
Craig Jeffery Michael	GC & Corporate Secretary	Jan 06 '25	Sale	7.33	2,486	18,222	7,558	Jan 08 08:57 PM
Matushak Jay	Chief Financial Officer	Jan 06 '25	Sale	7.33	4,970	36,430	17,747	Jan 08 08:55 PM
Orozco Tomas	EVP, Consumer Care	Jan 06 '25	Sale	7.33	1,233	9,038	7,830	Jan 08 08:54 PM
Mikan George Lawrence III	CEO & President	Jan 06 '25	Sale	7.33	31,798	233,079	146,539	Jan 08 08:53 PM
Mikan George Lawrence III	CEO & President	Dec 17 '24	Sale	4.18	16,803	70,237	83,029	Dec 18 09:15 PM

ADAP Adaptimmune Therapeutics Plc ADR daily Stock Chart

Peers: IOVA FATE ALLO ADPT BLRX CGEN AFMD IMTX TPST

| Held by: SPDW

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	3.64%	Shs Outstand	265.05M	Perf Week	-4.50%
Market Cap	35.44M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	-89.68%	Shs Float	255.41M	Perf Month	226.10%
Enterprise Value	58.06M	PEG	-	EPS next Q	-0.05	Inst Own	27.58%	Short Float	9.03%	Perf Quarter	-47.15%
Income	-169.79M	P/S	0.54	EPS this Y	-60.00%	Inst Trans	-7.02%	Short Ratio	0.30	Perf Half Y	-48.20%
Sales	65.66M	P/B	-	EPS next Y	-136.67%	ROA	-75.07%	Short Interest	23.05M	Perf YTD	-75.18%
Book/sh	-0.27	P/C	1.36	EPS next 5Y	-11.87%	ROE	-1341.37%	52W High	0.96 -86.13%	Perf Year	-84.71%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	34.83% 26.53%	ROIC	-	52W Low	0.04 231.76%	Perf 3Y	-87.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.12% 175.28%	Gross Margin	78.45%	Volatility	14.33% 26.26%	Perf 5Y	-98.25%
Dividend TTM	-	EV/Sales	0.88	EPS Y/Y TTM	-93.14%	Oper. Margin	-236.46%	ATR (14)	0.03	Perf 10Y	-98.85%
Dividend Ex-Date	-	Quick Ratio	1.29	Sales Y/Y TTM	-53.61%	Profit Margin	-258.57%	RSI (14)	55.08	Recom	3.67
Dividend Gr. 3/5Y	- -	Current Ratio	1.52	EPS Q/Q	-143.43%	SMA20	17.57%	Beta	2.38	Target Price	0.28
Payout	-	Debt/Eq	-	Sales Q/Q	-89.22%	SMA50	52.51%	Rel Volume	0.44	Prev Close	0.15
Employees	506	LT Debt/Eq	-	Earnings	Aug 13 BMO	SMA200	-57.40%	Avg Volume	77.14M	Price	0.13
IPO	May 06, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	52.38% 59.05%	Trades		Volume	35,527,692	Change	-12.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-25	Downgrade	Mizuho	Outperform → Neutral	$0.50
Jul-30-24	Initiated	H.C. Wainwright	Buy	$4
May-30-24	Initiated	Scotiabank	Sector Outperform	$3.15
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Aug-13-25 07:30AM	Adaptimmune Reports Q2 Financial Results and Provides Business Update (Newsfile)
Aug-04-25 04:00PM	US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel (PR Newswire) +19.92%
Jul-28-25 07:30AM	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds (Newsfile) -71.17%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
May-14-25 03:05AM	Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... (GuruFocus.com) +8.80%
07:30AM	Loading…
May-13-25 07:30AM	Adaptimmune Reports Q1 Financial Results and Provides Business Update (Newsfile) -15.31%
May-12-25 09:48AM	What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings (GuruFocus.com)
May-07-25 12:00PM	Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 (Newsfile)
Mar-21-25 12:05PM	Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result (GuruFocus.com)
03:01AM	Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
Mar-20-25 12:10PM	Adaptimmune targets $400M sarcoma franchise peak sales by 2027 (SeekingAlpha) -37.65%
12:10PM	Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00AM	Adaptimmune Provides Q4 and Full Year 2024 Business Update (Newsfile)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
Mar-18-25 07:00AM	From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines (FastCompany)
04:54PM	Loading…
Mar-12-25 04:54PM	Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 (Newsfile)
Jan-30-25 04:00PM	Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 (Newsfile)
Jan-13-25 08:00AM	Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) (Newsfile)
Dec-19-24 07:30AM	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK (Newsfile)
Dec-02-24 04:00PM	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) (Newsfile)
Nov-15-24 05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 11:55AM	Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints (Pharmaceutical Technology) -23.28%
02:15AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... (GuruFocus.com)
Nov-13-24 04:05PM	Adaptimmune Reports Q3 2024 Financial and Business Updates (Newsfile)
09:00AM	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial (Newsfile)
Nov-05-24 09:19AM	Adaptimmune to Participate in Scientific and Medical Conferences this November and December (Newsfile)
Oct-31-24 05:20PM	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 (Newsfile) +10.23%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.41%
Aug-28-24 08:00AM	Adaptimmune to Participate in Two Bank Conferences this September (Newsfile)
07:00AM	Loading…
Aug-12-24 07:00AM	Adaptimmune Reports Q2 2024 Financial and Business Updates (Newsfile) +9.82%
Aug-09-24 07:13AM	Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval (Pharmaceutical Technology)
Aug-05-24 08:00AM	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 (Newsfile) -16.24%
Aug-02-24 11:53AM	Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma (Pharmaceutical Technology) -7.87%
08:46AM	FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade (Benzinga)
06:54AM	First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer (BioPharma Dive)
Aug-01-24 08:20PM	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor (Business Wire)
Jul-24-24 11:13PM	Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now? (Insider Monkey) +5.69%
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jun-03-24 12:00PM	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise (Newsfile) -5.31%
May-31-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +11.88%
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-17-24 06:49AM	Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating (MT Newswires) -7.50%
May-16-24 08:18AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-15-24 12:53PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.83%
11:07AM	Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital (MT Newswires)
07:30AM	Adaptimmune Reports Q1 2024 Financial and Business Updates (Newsfile)
07:00AM	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital (Newsfile)
May-01-24 12:00PM	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 (Newsfile)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire) +12.87%
Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05% -8.00%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks) +7.11%
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wood Gavin	Chief Financial Officer	Sep 02 '25	Sale	0.01	96,000	950	0	Sep 03 05:00 PM
Gavin Wood	Chief Financial Officer	Sep 02 '25	Proposed Sale	0.06	16,000	942		Sep 02 08:00 AM
Bertrand William C JR	Chief Operating Officer	Aug 28 '25	Sale	0.01	207,000	2,091	986,352	Aug 29 06:25 PM
William Bertrand	Chief Operating Officer	Aug 28 '25	Proposed Sale	0.06	34,500	2,070		Aug 29 06:24 PM
Behbahani Ali	Director	Aug 18 '25	Sale	0.01	14,671,794	176,062	0	Aug 19 07:07 PM
Behbahani Ali	Director	Aug 15 '25	Sale	0.01	4,828,206	53,110	14,671,794	Aug 19 07:07 PM
New Enterprise Associates, 14	Affiliate	Aug 15 '25	Proposed Sale	0.07	13,829,778	981,914		Aug 15 04:24 PM
New Enterprise Associates, 16	Affiliate	Aug 15 '25	Proposed Sale	0.07	3,250,000	230,750		Aug 15 04:23 PM
EcoR1 Capital, LLC	10% Owner	Jul 28 '25	Sale	0.11	33,931,740	3,817,321	130,492,680	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 30 '25	Sale	0.10	27,433,338	2,800,944	100,371,882	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 29 '25	Sale	0.10	2,687,460	271,971	127,805,220	Jul 30 06:20 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:16 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Sale	0.58	30,601	17,773	44,327	Jan 17 09:15 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 03:07 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:59 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:50 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Proposed Sale	0.58	30,601	17,772		Jan 17 02:42 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Sale	0.59	30,473	17,915	17,801	Jan 15 04:19 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 15 '25	Sale	0.57	29,096	16,724	41,582	Jan 15 04:19 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Sale	0.57	12,991	7,467	18,421	Jan 15 04:18 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Sale	0.59	12,392	7,285	5,845	Jan 15 04:17 PM
Norry Elliot	Chief Medical Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:17 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:16 PM
Lunger John	Chief Patient Supply Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:16 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 04:01 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Proposed Sale	0.57	12,991	7,467		Jan 15 03:55 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Proposed Sale	0.59	12,392	7,286		Jan 15 03:50 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 03:43 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Proposed Sale	0.59	30,473	17,917		Jan 15 03:34 PM

Open in Screener

MBX

MBX Biosciences Inc

Oct 06 • 04:00PM ET

16.26

-0.43 -2.58 %

Healthcare • Biotechnology • USA • NASD

MBX MBX Biosciences Inc daily Stock Chart

Held by: VTI IWM IWN SCHA VXF VTWO FESM IWC SBIO BBC

Index	RUT	P/E	-	EPS (ttm)	-2.31	Insider Own	53.79%	Shs Outstand	33.59M	Perf Week	-9.36%
Market Cap	727.07M	Forward P/E	-	EPS next Y	-2.80	Insider Trans	2.88%	Shs Float	20.67M	Perf Month	40.78%
Enterprise Value	502.83M	PEG	-	EPS next Q	-0.70	Inst Own	42.94%	Short Float	20.45%	Perf Quarter	24.41%
Income	-77.02M	P/S	-	EPS this Y	53.36%	Inst Trans	2.76%	Short Ratio	3.82	Perf Half Y	169.21%
Sales	0.00M	P/B	2.49	EPS next Y	-3.05%	ROA	-52.32%	Short Interest	4.23M	Perf YTD	-11.77%
Book/sh	6.53	P/C	3.23	EPS next 5Y	17.25%	ROE	-56.28%	52W High	27.50 -40.87%	Perf Year	-30.98%
Cash/sh	5.03	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-35.05%	52W Low	4.81 238.26%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.73% 11.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.50	EPS Q/Q	-22.16%	SMA20	12.14%	Beta	1.08	Target Price	60.29
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.25%	Rel Volume	0.96	Prev Close	16.69
Employees	43	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	SMA200	36.08%	Avg Volume	1.11M	Price	16.26
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.06% -	Trades		Volume	1,062,766	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
04:14PM	Loading…
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:37AM	Loading…
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
08:00AM	Loading…
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM

NEUE

NeueHealth Inc

ADAP

Adaptimmune Therapeutics Plc ADR

MBX

MBX Biosciences Inc

Upgrade your FINVIZ experience